Celcuity (NASDAQ:CELC) Posts Earnings Results, Beats Expectations By $0.30 EPS

Posted by Francis Steltz on Nov 7th, 2026

Celcuity (NASDAQ:CELC – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.21) EPS for the quarter, beating the consensus estimate of ($1.51) by $0.30, FiscalAI reports.

Here are the key takeaways from Celcuity’s conference call:

Commercial launch of REVTORPYK is off to a strong early start: within about a month of availability, 78% of Celcuity’s 36 priority accounts had ordered the drug, and 91% of U.S. commercial and Medicare lives were covered. The company also reported a preferred NCCN recommendation and inclusion in three of four major provider pathways.
VIKTORIA-1 results presented at ESMO showed encouraging efficacy across patient subgroups, including median progression-free survival of 21.5 months for the triplet in patients without liver metastases, and higher response rates than the comparator. Celcuity also highlighted lower treatment-discontinuation rates with gedatolisib regimens, while noting the results are from clinical trials.
Potential growth extends beyond the current second-line indication: Celcuity expects to submit data for the PIK3CA-mutant cohort to global regulators, is conducting first-line breast cancer trials, and plans a randomized phase II prostate cancer study in the first half of 2027. These programs remain subject to clinical and regulatory outcomes.
Third-quarter net loss widened to $73.3 million from $43.8 million a year earlier as operating expenses rose, largely reflecting commercial launch investment. Celcuity ended the quarter with $642.7 million in cash, equivalents and short-term investments and said it expects funding through 2029; it reported no product revenue in the quarter.

Celcuity Trading Up 4.3%

NASDAQ:CELC traded up $2.75 on Friday, reaching $66.79. The company’s stock had a trading volume of 1,081,623 shares, compared to its average volume of 1,806,096. Celcuity has a 12-month low of $53.54 and a 12-month high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. The stock has a 50 day moving average price of $75.11 and a 200 day moving average price of $99.38.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Citigroup reissued a “market outperform” rating on shares of Celcuity in a research report on Monday, October 19th. Zacks Research downgraded Celcuity from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. Craig Hallum reaffirmed a “buy” rating and set a $178.00 price objective on shares of Celcuity in a research note on Wednesday, July 15th. Royal Bank Of Canada cut shares of Celcuity to a “neutral” rating in a research report on Wednesday, October 28th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Celcuity in a research note on Thursday, September 17th. They issued an “overweight” rating and a $157.00 target price on the stock. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Celcuity presently has an average rating of “Moderate Buy” and an average price target of $152.14.

Check Out Our Latest Stock Analysis on CELC

Key Stories Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

Positive Sentiment: Celcuity reported a third-quarter loss of $1.21 per share, narrower than analysts’ expected loss of $1.51. The earnings beat may support sentiment. MarketBeat earnings report
Positive Sentiment: The Q3 earnings-call summary highlighted strong launch momentum for Revtorpic, a potential positive commercial catalyst. Q3 2026 earnings-call highlights
Positive Sentiment: Guggenheim kept its Buy rating and lowered its price target only modestly, from $171 to $169; the report cited substantial upside relative to the referenced share price. TickerReport article
Negative Sentiment: Celcuity’s Q3 adjusted loss widened, a counterpoint to the per-share earnings beat and a reminder that the company remains loss-making. Celcuity Q3 adjusted loss widens

About Celcuity

(Get Free Report)

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.